To study the efficacy of two antiviral drugs for the treatment of Glenmark Kovid-19

To study the efficacy of two antiviral drugs for the treatment of Glenmark Kovid-19

Let’s Start this Interesting Article Shared on

New Delhi: Glenmark Pharmaceuticals said on Tuesday that it will conduct a new study to test the combined efficacy of two antiviral drugs, favipirvir and umifenovir, as a potential COVID-19 treatment regimen.
The two antiviral drugs have different mechanisms of action, Glenmark said in a statement, and their combination may demonstrate improved treatment efficacy by effectively coping with high viral loads in early stage COVID-19 patients. Can.
The Glenmark study will examine whether early administration of a combination of favipirvir and umifenovir, both acting by different mechanisms, increases antiviral efficacy on COVID-19 patients, the pair added.
Said Monica Tandon, vice president and head, Glenmark Clinical Development Global Global / Branded Portfolio.
He said that the company hoped the study would be important to identify highly effective and safe treatments against COVID-19 in India.
Glenmark is already conducting phase 3 clinical trials of favipirvir as a COVID-19 monotherapy option with 150 patients enrolled from nine major government and private hospitals in the country.
The results of the monotherapy phase 3 clinical trial are expected by July or August.
The Mumbai-based drug firm was the first unit in the country to receive Drug Controller General of India (DCGI) approval for conducting favipirvir clinical trials against COVID-19.


Leave a Reply

Your email address will not be published. Required fields are marked *